> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hospira Recalls Injectable Vancomycin Due to Particulates
- URL: https://www.fdaweb.com/hospira-recalls-injectable-vancomycin-due-to-particulates/
- Published: 2023-01-06T12:00:00.000Z
- Updated: 2026-09-14T18:11:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153489

Hospira has recalled one lot of injectable vancomycin HCl single-dose fliptop 1.5 g vials due to two visible glass particulates observed in a single vial. “If administered intravenously, patients may experience adverse events such as local irritation or swelling, vasculitis/ phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism,” a [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-inc-issues-voluntary-nationwide-recall-one-lot-vancomycin-hydrochloride-injection-usp?ref=fdaweb.com) says. The antibiotic is indicated for the treating serious or severe infections caused by susceptible strains of methicillin-resistant *staphylococci*.